首页> 外文会议>International Conference on Biomedical Engineering, Machinery and Earth Science >Intratumor Heterogeneity of EGFR Activating Mutations in Advanced NSCLC Patients at Single-Cell Level

【24h】

Intratumor Heterogeneity of EGFR Activating Mutations in Advanced NSCLC Patients at Single-Cell Level

机译：单细胞水平晚期NSCLC患者EGFR激活突变的细胞内异质性

获取原文

页面导航

著录项
相似文献
相关主题

著录项

来源
《International Conference on Biomedical Engineering, Machinery and Earth Science》|2018年|1 CD-ROM|共10页
会议地点
作者
Liu Yuefen;
展开▼
作者单位

展开▼
会议组织
原文格式 PDF
正文语种
中图分类生物工程学（生物技术）;
关键词

相似文献

外文文献
中文文献
专利

1. Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level [J] . Longhua Guo, Zhihong Chen, Chongrui Xu, BMC Cancer . 2019,第1期

机译：高级NSCLC患者EGFR激活突变在单细胞水平下的肿瘤内异质性
2. Noninvasive monitoring of acquired EGFR-T790M mutation and discovery of its heterogeneity in patients with advanced NSCLC treated with EGFR-TKI [J] . Ye X., Zheng D., Zhang M. Z., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2014,第Suppla6期

机译：EGFR-TKI治疗的晚期NSCLC患者无创监测获得性EGFR-T790M突变及其异质性的发现
3. P3.02b-064 Time to EGFR-TKI Treatment for Patients with Advanced NSCLC and EGFR Activating Mutation in a Tertiary Cancer Center [J] . Jennifer Le Guévelou, Audrey Dugué, Nicolas Richard, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第1期

机译：P3.02B-064达到高级NSCLC和EGFR激活突变患者的EGFR-TKI治疗的时间
4. Intratumor Heterogeneity of EGFR Activating Mutations in Advanced NSCLC Patients at Single-Cell Level [C] . Liu Yuefen International Conference on Biomedical Engineering, Machinery and Earth Science . 2018

机译：单细胞水平晚期NSCLC患者EGFR激活突变的细胞内异质性
5. The implications of molecular diagnostics in clinicopathologic correlations in two disease processes: PSA serum levels in acute illnesses, and, prevalence of activated protein C resistance and factor V mutation in patients with thrombosis and in control patients by ethnic group. [D] . Honda, Stacey Ann Akemi. 2002

机译：分子诊断在两种疾病过程中的临床病理相关性中的意义：急性疾病中PSA血清水平，以及血栓形成患者和对照患者（按种族）的活化蛋白C抗性和因子V突变的患病率。
6. Intratumoral heterogeneity of EGFR-activating mutations in advanced NSCLC patients at the single-cell level [O] . Longhua Guo, Zhihong Chen, Chongrui Xu, 2019

机译：晚期NSCLC患者单细胞水平的EGFR激活突变的肿瘤内异质性
7. DDX3X induces primary EGFR-TKI resistance based on intratumor heterogeneity in lung cancer cells harboring EGFR-activating mutations. [O] . Koichiro Nozaki, Hiroshi Kagamu, Satoshi Shoji, 2014

机译：DDX3X基于具有EGFR激活突变的肺癌细胞中的肿瘤内异质性诱导原发性EGFR-TKI抗性。

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号